Item 3.01 Other Events.

The information set forth under Item 8.01 of this Current Report on Form 8-K is hereby incorporated by reference in this Item 3.01.





Item 8.01 Other Events.

On December 10, 2019, the United States Bankruptcy Court for the District of Delaware entered an order approving the sale of the assets of Sienna Biopharmaceuticals, Inc. (the "Company") related to SNA-001, including all of the Company's intellectual property related thereto (the "Sale Order"), for an aggregate purchase price of $1,700,000 in cash, pursuant to an auction process under Chapter 11 of Title 11 of the United States Code. The Company did not receive bids for any of its other assets.

Following such approval, on December 10, 2019, the Company notified the Nasdaq Hearings Panel (the "Panel") of the Nasdaq Stock Market ("Nasdaq") of the Company's withdrawal from the Panel's hearing process, and requested that Nasdaq delist the Company's common stock from Nasdaq, effective as of December 13, 2019. The Company anticipates that the Chapter 11 process will be converted to a Chapter 7 proceeding.

The foregoing description is a summary of the Sale Order and does not purport to be complete, and is subject to, and qualified in its entirety by reference to, the Sale Order notice, a copy of which is available at a website administered by the Company's claims agent, Epiq, at http://dm.epiq11.com/Sienna. For additional information related to the Company's bankruptcy process, please see the foregoing website.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses